Rhumbline Advisers Increases Stock Position in Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Rhumbline Advisers boosted its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR – Free Report) by 8.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,814 shares of the biotechnology company’s stock after purchasing an additional 3,731 shares during the quarter. Rhumbline Advisers’ […]
Rhumbline Advisers boosted its position in Capricor Therapeutics, Inc. (NASDAQ:CAPR – Free Report) by 8.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,814 shares of the biotechnology company’s stock after purchasing an additional 3,731 shares during the quarter. Rhumbline Advisers’ […]
